Menu
GOVPH
  • Home
  • HTA Governance
    • Universal Health Care Act
    • Administrative Order on HTA
    • Philippine HTA Process Guide
    • Philippine HTA Methods Guide
    • Philippine HTA Code of Conduct
    • HTA Philippines Social Values Guide
  • About Us
    • Mission/Vision
    • Health Technology Assessment Council (HTAC)
    • Health Technology Assessment Division (HTAD)
    • HTA Philippines Annual Report
      • 2021 HTA Annual Report
      • 2020 HTA Annual Report
      • 2019 HTA Annual Report
    • Road to HTA Institutionalization
    • External Partners
  • Assessments
  • Issuances
  • Evidence Briefs
  • FAQs
  • Get Involved with Us
    • Careers
    • Contact Us
    • Call for Nomination
    • Topic Nomination
  • AUXILIARY MENU
  • GOVPH
  • Home
  • HTA Governance
    • Universal Health Care Act
    • Administrative Order on HTA
    • Philippine HTA Process Guide
    • Philippine HTA Methods Guide
    • Philippine HTA Code of Conduct
    • HTA Philippines Social Values Guide
  • About Us
    • Mission/Vision
    • Health Technology Assessment Council (HTAC)
    • Health Technology Assessment Division (HTAD)
    • HTA Philippines Annual Report
      • 2021 HTA Annual Report
      • 2020 HTA Annual Report
      • 2019 HTA Annual Report
    • Road to HTA Institutionalization
    • External Partners
  • Assessments
  • Issuances
  • Evidence Briefs
  • FAQs
  • Get Involved with Us
    • Careers
    • Contact Us
    • Call for Nomination
    • Topic Nomination

HTAC Recommendation

Evidence Summary on AstraZeneca COVID-19 vaccine as Second Booster/ Fourth Dose for the prevention of COVID-19

nimble_asset_Website-banner-Assessments

HTAC RECOMMENDATION ON THE PNF INCLUSION OF abiraterone acetate in combination with prednisone and enzalutamide for individuals with metastatic castration-resistant prostate cancer

nimble_asset_Website-banner-Assessments

HTAC RECOMMENDATION ON THE PNF INCLUSION OF REMDESIVIR FOR ADULT PATIENTS WITH COVID-19 REQUIRING HOSPITALIZATION

HTAC Recommendation on COVID-19 Moderna for children 6 to 11 years old

HTAC Recommendation for the Inclusion of Zoledronic Acid for Individuals with Malignancy-Related Bone Disease in the Philippine National Formulary (PNF)

HTAC Guidance: Limited evidence of improved protection from 2nd booster dose among healthy individuals aged 18-49 years

HTAC Recommendation on CoronaVac COVID-19 Vaccine for children 6 to 17 years old

HTAC Recommendation on the Second Booster of COVID-19 vaccines for the prevention of COVID-19 among individuals aged 50 years old and older and individuals with comorbidities aged 18 to 49 years old

HTAC Guidance: Self-Administered Antigen Test Kits (SAAgT)